Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$0.98
EPS est.
$0.72
EPS surprise
+36.11%
1-day move
+15.05%
LivaNova's strong earnings per share performance exceeded expectations, which likely contributed to the stock's significant increase of 15.05% in response. However, the lack of revenue details and management commentary leaves some uncertainty about overall performance and future direction. Investors may want to watch for more information in upcoming reports.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.98 | $0.90 | +36.11% |
| Revenue | N/A | $346M | N/A |
No transcript is on record, so the analysis is based solely on numerical results.
LivaNova PLC is a health care company specializing in medical devices and therapies. With a market cap of $3 billion, it plays a crucial role in the health care equipment sector, focusing on innovative solutions that improve patient outcomes.
Last quarter
In Q4 2025, LivaNova reported an EPS of $0.86, beating expectations by 28.94%. The stock reacted positively, gaining 1.80% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+38.31%
Avg 1-day reaction
+2.33%
Analysts expect LivaNova to report solid earnings this quarter, with a consensus EPS of $0.90 and revenue of $346 million. Investors are keen to see if the company can maintain its strong performance.
Bull case
If LivaNova exceeds EPS estimates, it could signal robust demand for its products and lead to a positive stock reaction, continuing its trend of beating earnings expectations.
Bear case
Conversely, if the company misses EPS or revenue estimates, it may raise concerns about its growth trajectory and market competitiveness, potentially leading to a negative stock reaction.
Key metrics to watch
EPS
$0.90Earnings per share is a key indicator of profitability and can influence investor sentiment.
Revenue
$346MRevenue figures provide insight into the company's sales performance and overall market demand.
The print will turn on these.
Q1
Will LivaNova's EPS exceed the consensus estimate of $0.90?
A beat on EPS could reinforce investor confidence and support a positive stock reaction.
Q2
What is the revenue outlook for the upcoming quarters?
Revenue guidance will be critical in assessing the company's growth potential and market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate LivaNova's ability to leverage recent product innovations, which could drive higher-than-expected revenue growth.
Supporting evidence
LivaNova has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
The options market is pricing a larger move than historical averages, suggesting potential for a significant surprise.
Key risk
If revenue growth exceeds $351 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating LivaNova's ability to sustain its growth trajectory amidst competitive pressures.
Bull confirmed if
An EPS of $1.03 or higher would confirm strong operational performance.
Bear confirmed if
An EPS below $0.75 would raise concerns about profitability and market demand.
What the market is pricing for the move.
Implied Move
±12.48%
Historical Avg
±10.6%
The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±12.2% while LIVN has averaged ±10.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
32.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
112.89%
of float
Insider
0.41%
of float
Holders
449
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
7,565,342 sh · $574.4M
13.73%
6.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If LivaNova beats expectations, history suggests the stock could rise by an average of 2.58%, confirming strong demand.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a significant drop, with historical patterns indicating a potential decline based on past reactions.
The lines on the call that would change the story.
Primecap Management Company
4,168,377 sh · $316.5M
7.57%
-0.9%
FMR, LLC
3,147,068 sh · $239.0M
5.71%
18.0%
Hood River Capital Management LLC
2,565,477 sh · $194.8M
4.66%
303.0%
AQR Capital Management, LLC
2,356,191 sh · $178.9M
4.28%
-5.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.